treatment
Ask the Pediatric Expert
When Does a PNH Clone Have Clinical Significance?
VEXAS Syndrome
David Beck, MD, PhD
Beck, David
Assistant Professor, Department of Medicine
NYU Grossman School of Medicine
My research focuses on identifying the genetic causes of human diseases as a means to both better diagnosis and treat patients and understand basic biologic principles. We are interested in studying autoimmune and auto-inflammatory diseases to elucidate the mechanism underlying these diseases and improve patient care. We use a combination of genetic, and biochemical approaches in patient derived and animal models to better understand these diseases. Our aim is to directly connect human diseases with basic innate immune biology using genetics.
Online Profile:
Suresh Balasubramanian
Balasubramanian, Suresh
Physician, Oncology - Hematology, Oncology - Medical
Karmanos Cancer Institute
Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics.
Online Profile:
Catherine J. Lee, MD
Lee, Catherine
Associate Professor of Medicine
Fred Hutchinson Cancer Research Center
Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.
Online Profile:
Advances in Treatment of PNH
In this webinar, Dr. Jaroslaw Maciejewski discusses the recent advances in treating PNH including treatments recently approved as well as what's in the pipeline. The recording includes the question and answer section.
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
June 2, 2022
- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant –
- Omidubicel has Orphan Drug Designation and Breakthrough Therapy Designation -
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
BOSTON, May 25, 2022 – Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and Drug Administration (FDA) approved TIBSOVO® (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated